Home » Stocks » Harvard Bioscience

Harvard Bioscience, Inc. (HBIO)

Stock Price: $3.11 USD -0.07 (-2.20%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $3.15 +0.04 (1.29%) Aug 3, 7:00 AM

Stock Price Chart

Key Info

Market Cap 119.36M
Revenue (ttm) 111.75M
Net Income (ttm) -6.83M
Shares Out 38.38M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE 39.22
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $3.11
Previous Close $3.18
Change ($) -0.07
Change (%) -2.20%
Day's Open 3.14
Day's Range 3.03 - 3.19
Day's Volume 89,847
52-Week Range 1.39 - 3.77

More Stats

Market Cap 119.36M
Enterprise Value 172.73M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.38M
Float 34.06M
EPS (basic) -0.18
EPS (diluted) -0.18
FCF / Share 0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 6.36%
Payout Ratio n/a
Shares Short 2.45M
Short Ratio 2.32
Short % of Float 3.87%
Beta 1.57
PE Ratio n/a
Forward PE 39.22
P/FCF Ratio 15.72
PS Ratio 1.07
PB Ratio 1.61
Revenue 111.75M
Operating Income -2.78M
Net Income -6.83M
Free Cash Flow 7.59M
Net Cash -53.37M
Net Cash / Share -1.39
Gross Margin 57.77%
Operating Margin -2.48%
Profit Margin -6.10%
FCF Margin 6.79%
ROA -0.41%
ROE -8.74%
ROIC -2.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
(28.62% upside)
Low
4.00
Current: $3.11
High
4.00
Target: 4.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11612177.41105109109105111109108
Revenue Growth-3.81%56.02%-25.94%-3.81%0%3.32%-5.4%2.12%0.63%-
Gross Profit64.3263.1839.1748.4248.7249.3447.7052.3450.1951.81
Operating Income0.380.98-0.64-3.00-1.716.621.547.838.4110.22
Net Income-4.69-2.92-0.87-4.31-19.042.36-1.832.373.8119.02
Shares Outstanding37.8136.4534.7534.2133.5932.1730.3828.8028.4528.97
Earnings Per Share-0.12-0.08-0.02-0.13-0.570.07-0.060.080.130.65
EPS Growth--------38.46%-80%-
Operating Cash Flow8.052.881.065.380.714.354.068.066.6512.29
Capital Expenditures-1.22-0.99-0.88-1.45-2.95-0.86-1.56-1.74-1.48-0.81
Free Cash Flow6.831.900.183.94-2.253.492.506.335.1711.48
Cash & Equivalents8.348.175.195.606.7414.1325.7720.6817.9219.70
Total Debt64.4760.8011.7513.7518.7321.4524.7512.9516.3018.01
Net Cash / Debt-56.13-52.62-6.56-8.15-11.99-7.321.027.731.621.70
Assets165169109108120136135133127125
Liabilities83.1885.8928.4535.5742.4540.4540.9829.2731.1434.55
Book Value81.6982.7280.9072.2077.6095.4794.4910495.5090.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Harvard Bioscience, Inc.
Country United States
Employees 505
CEO James W. Green

Stock Information

Ticker Symbol HBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: HBIO
IPO Date December 7, 2000

Description

Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion and temperature controllers, and microincubation and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products in approximately 100 countries through sales organizations, Websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.